Adaptive Biotechnologies (ADPT) FCF Margin (2018 - 2026)
Adaptive Biotechnologies (ADPT) posted FCF Margin of 13.68% for Q1 2026, down 791.08% sequentially from 1.98% in Q4 2025, and up 4303.0% YoY from 0.31% in Q1 2025.
Adaptive Biotechnologies (ADPT) FCF Margin (2018 - 2026) Analysis & Trends
Adaptive Biotechnologies has reported FCF Margin for 9 years, with the latest figure at 13.68% in Q1 2026.
- Quarterly FCF Margin rose 4303.0% year-over-year to 13.68% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 9.78% (up 3579.0% YoY) and the FY2025 annual result came in at 17.67%, up 3625.0% from the prior year.
- FCF Margin declined to 13.68% in Q1 2026 per ADPT's latest filing, from 1.98% in the prior quarter.
- Over five years, FCF Margin peaked at 1.98% in Q4 2025 and troughed at 284.71% in Q2 2023.
- A 5-year average of 80.83% and a median of 57.47% in 2023 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2023 and 2024: FCF Margin slumped 16449 bps in 2023, then soared 24742 bps in 2024.
- Over 5 years, FCF Margin stood at 32.48% in 2022, then slumped by 77 bps to 57.47% in 2023, then jumped by 50 bps to 28.94% in 2024, then jumped by 107 bps to 1.98% in 2025, then plunged by 791 bps to 13.68% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 13.68%, 1.98%, and 9.82% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 213.88 Bn | 209.81 Bn | 8.34 Bn | 13.97% |
| 2 | Danaher | 140.65 Bn | 136.30 Bn | 3.61 Bn | 20.19% |
| 3 | Idexx Laboratories | 46.02 Bn | 45.83 Bn | 779.09 Mn | 26.51% |
| 4 | Agilent Technologies | 39.85 Bn | 38.05 Bn | 990.00 Mn | 10.95% |
| 5 | Iqvia Holdings | 39.20 Bn | 37.12 Bn | 1.44 Bn | 8.24% |
| 6 | Natera | 38.80 Bn | 37.70 Bn | 696.04 Mn | 2.59% |
| 7 | Illumina | 30.11 Bn | 28.94 Bn | 770.00 Mn | 13.89% |
| 8 | Mettler Toledo International | 28.66 Bn | 28.61 Bn | 650.22 Mn | 27.51% |
| 9 | Quest Diagnostics | 26.24 Bn | 25.61 Bn | 1.03 Bn | 15.08% |
| 10 | Adaptive Biotechnologies | 3.80 Bn | 3.58 Bn | 52.17 Mn | -13.68% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.68% |
| Dec 31, 2025 | 1.98% |
| Sep 30, 2025 | -9.82% |
| Jun 30, 2025 | -19.35% |
| Mar 31, 2025 | -56.71% |
| Dec 31, 2024 | -28.94% |
| Sep 30, 2024 | -57.67% |
| Jun 30, 2024 | -37.29% |
| Mar 31, 2024 | -95.20% |
| Dec 31, 2023 | -57.47% |
| Sep 30, 2023 | -123.16% |
| Jun 30, 2023 | -284.71% |
| Mar 31, 2023 | -164.89% |
| Dec 31, 2022 | -32.48% |
| Sep 30, 2022 | -100.02% |
| Jun 30, 2022 | -120.22% |
| Mar 31, 2022 | -174.53% |
| Dec 31, 2021 | -166.28% |
| Sep 30, 2021 | -147.12% |
| Jun 30, 2021 | -175.03% |